



(51) International Patent Classification:

A61K 38/12 (2006.01) *C07K 7/06* (2006.01)
A61P 25/28 (2006.01) *C07K 7/64* (2006.01)
C07K 19/00 (2006.01) *A61K 39/39* (2006.01)

(21) International Application Number:

PCT/US2021/033222

(22) International Filing Date:

19 May 2021 (19.05.2021)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/027,150	19 May 2020 (19.05.2020)	US
63/062,903	07 August 2020 (07.08.2020)	US
63/140,917	24 January 2021 (24.01.2021)	US

(71) Applicant: **OTHAIR PROTHENA LIMITED** [IE/IE];
 77 Sir John Rogerson's Quay, Block C, Grand Canal Dock-
 lands, Dublin 2, D02 VK60 (IE).

(72) Inventors; and

(71) Applicants: **BARBOUR, Robin** [US/US]; 250 Normandy
 Lane, Walnut Creek, CA 94598 (US). **KINNEY, Gene**
 [US/US]; 2800 S Ocean Blvd, Unit 14L/M, Boca Raton,
 FL 33432 (US). **ZAGO, Wagner** [US/US]; 1291 Crestview
 Drive, San Carlos, CA 94070 (US). **NIJJAR, Tarlochan,**
 S. [US/US]; 712 Ironbark Court, Orinda, CA 94563 (US).

(74) Agent: **GATTARI, Patrick, G.**; McDonnell Boehnen Hul-
 bert & Berghoff LLP, 300 South Wacker Drive, Chicago,
 IL 60606 (US).

(81) Designated States (unless otherwise indicated, for every
 kind of national protection available): AE, AG, AL, AM,
 AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
 CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,
 DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,

(54) Title: MULTI-EPIOTOPE VACCINE FOR THE TREATMENT OF ALZHEIMER'S DISEASE




FIG. 5A

(57) Abstract: The disclosure provides peptide compositions and immunotherapy compositions comprising an amyloid-beta (A β) peptide and a tau peptide. The disclosure also provides methods of treating or effecting prophylaxis of Alzheimer's disease or other diseases with beta-amyloid deposition in a subject, including methods of clearing deposits, inhibiting or reducing aggregation of A β and/or tau, blocking the uptake by neurons, clearing amyloid, and inhibiting propagation of tau seeds in a subject having or at risk of developing Alzheimer's disease or other diseases containing tau and/or amyloid-beta accumulations. The methods include administering to such patients the compositions comprising an amyloid-beta (A β) peptide and a tau peptide.

[Continued on next page]

HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN,
KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD,
ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO,
NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW,
SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN,
TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

- (84) Designated States** (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))
- with sequence listing part of description (Rule 5.2(a))

(88) Date of publication of the international search report:

30 December 2021 (30.12.2021)